ATE547104T1 - Zusammensetzung enthaltend einen lungensurfactant und sildenafil zur behandlung von lungenerkrankungen - Google Patents
Zusammensetzung enthaltend einen lungensurfactant und sildenafil zur behandlung von lungenerkrankungenInfo
- Publication number
- ATE547104T1 ATE547104T1 AT04741805T AT04741805T ATE547104T1 AT E547104 T1 ATE547104 T1 AT E547104T1 AT 04741805 T AT04741805 T AT 04741805T AT 04741805 T AT04741805 T AT 04741805T AT E547104 T1 ATE547104 T1 AT E547104T1
- Authority
- AT
- Austria
- Prior art keywords
- lung
- treatment
- sildenafil
- composition containing
- surfactant
- Prior art date
Links
- 239000003580 lung surfactant Substances 0.000 title abstract 3
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 title 2
- 208000019693 Lung disease Diseases 0.000 title 1
- 229940066294 lung surfactant Drugs 0.000 title 1
- 229960003310 sildenafil Drugs 0.000 title 1
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 2
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 2
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 abstract 1
- 230000001627 detrimental effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000007257 malfunction Effects 0.000 abstract 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03013615 | 2003-06-16 | ||
| PCT/EP2004/051120 WO2004110450A1 (en) | 2003-06-16 | 2004-06-15 | Composition comprising a pulmonary surfactant and a pde5 inhibitor for the treatment of lung diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE547104T1 true ATE547104T1 (de) | 2012-03-15 |
Family
ID=33547593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04741805T ATE547104T1 (de) | 2003-06-16 | 2004-06-15 | Zusammensetzung enthaltend einen lungensurfactant und sildenafil zur behandlung von lungenerkrankungen |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7238664B2 (de) |
| EP (1) | EP1638567B1 (de) |
| JP (1) | JP2006527737A (de) |
| AT (1) | ATE547104T1 (de) |
| CA (1) | CA2529007C (de) |
| ES (1) | ES2383206T3 (de) |
| WO (1) | WO2004110450A1 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100891595B1 (ko) | 2005-02-28 | 2009-04-03 | 주식회사 케이티앤지 | 혈액 단백질의 삼출을 감소시키는 조성물 |
| CA2600636A1 (en) * | 2005-03-09 | 2006-09-14 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions based on anticholinergics and pde 5-inhibitors |
| GB0511066D0 (en) * | 2005-05-31 | 2005-07-06 | Novartis Ag | Organic compounds |
| WO2007033239A2 (en) * | 2005-09-13 | 2007-03-22 | Elan Pharma International, Limited | Nanoparticulate tadalafil formulations |
| WO2007097502A1 (en) * | 2006-02-23 | 2007-08-30 | Kt & G Corporation | Composition for reducing the exudation of serum proteins |
| CA2663436A1 (en) | 2006-10-04 | 2008-04-10 | Pfizer Products Inc. | Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists |
| CN101754747A (zh) * | 2007-06-05 | 2010-06-23 | Paka肺部医药公司 | 用于向肺脏递送药物的方法以及组合物 |
| WO2010013925A2 (en) * | 2008-07-31 | 2010-02-04 | Dong-A Pharmaceutical. Co., Ltd. | Pharmacological composition for prevention and treatment of respiratory disease containing pyrazolopyrimidinone compound or pharmaceutically acceptable salts thereof |
| EP2370068A4 (de) * | 2008-12-10 | 2015-09-23 | Paka Pulmonary Pharmaceuticals Inc | Verfahren und zusammensetzungen zur abgabe von medikamenten an die lunge |
| AU2010253770B9 (en) | 2009-05-29 | 2015-02-12 | Pearl Therapeutics, Inc. | Compositions for respiratory delivery of active agents and associated methods and systems |
| US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
| US20140275517A1 (en) | 2013-03-15 | 2014-09-18 | Pearl Therapeutics, Inc. | Methods and systems for conditioning of particulate crystalline materials |
| EP3082428A4 (de) | 2013-12-09 | 2017-08-02 | Respira Therapeutics, Inc. | Pde5-inhibitorpulverformulierungen und zugehörige verfahren |
| US10058545B2 (en) * | 2016-08-09 | 2018-08-28 | Cipla Limited | Method of treating pulmonary arterial hypertension |
| WO2025095852A1 (en) * | 2023-11-01 | 2025-05-08 | Asg Inspiration Laboratory (Singapore) Pte. Ltd. | Pharmaceutical composition for dry powder inhalation and preparation method thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4434629C1 (de) | 1994-09-28 | 1996-06-27 | Byk Gulden Lomberg Chem Fab | Zusammensetzungen zur Behandlung von IRDS und ARDS |
| DE69835594T2 (de) * | 1997-02-17 | 2007-08-16 | Altana Pharma Ag | Zusammensetzungen zur behandlung von irds oder ards die 3-(cyclopropylmethoxy)-n-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy) benzamid und lungensurfactant enthalten |
| DE19827907C2 (de) | 1998-06-23 | 2003-05-15 | Altana Pharma Ag | Neue pharmazeutische Zusammensetzungen zur Behandlung von IRDS und ARDS |
| JP2002529394A (ja) * | 1998-11-10 | 2002-09-10 | ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | 肺サーファクタント組成物を含有する治療セット |
| ATE314362T1 (de) | 1999-10-12 | 2006-01-15 | Takeda Pharmaceutical | Pyrimidin-5-carboximidverbindungen, verfahren zur herstellung derselben und deren verwendung |
| TW200400821A (en) * | 1999-11-02 | 2004-01-16 | Pfizer | Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient |
| CA2399944A1 (en) | 2000-02-11 | 2001-08-16 | Altana Pharma Ag | Novel use of pulmonary surfactant for the prophylaxis and treatment of chronic pulmonary diseases |
| AU2001265876A1 (en) * | 2000-04-12 | 2001-10-23 | Byk Gulden Lomberg Chemische Fabrik G.M.B.H. | Novel use of pulmonary surfactant for the prophylaxis or early treatment of acute pulmonary diseases |
| JP2005500349A (ja) | 2001-08-01 | 2005-01-06 | アルタナ ファルマ アクチエンゲゼルシャフト | 呼吸症候群のための選択的ｃｏｘ−２インヒビターと肺表面活性物質の組合せ物 |
-
2004
- 2004-06-15 WO PCT/EP2004/051120 patent/WO2004110450A1/en not_active Ceased
- 2004-06-15 ES ES04741805T patent/ES2383206T3/es not_active Expired - Lifetime
- 2004-06-15 JP JP2006516154A patent/JP2006527737A/ja active Pending
- 2004-06-15 AT AT04741805T patent/ATE547104T1/de active
- 2004-06-15 US US10/560,116 patent/US7238664B2/en not_active Expired - Fee Related
- 2004-06-15 CA CA2529007A patent/CA2529007C/en not_active Expired - Fee Related
- 2004-06-15 EP EP04741805A patent/EP1638567B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2529007C (en) | 2012-03-27 |
| CA2529007A1 (en) | 2004-12-23 |
| WO2004110450A1 (en) | 2004-12-23 |
| US7238664B2 (en) | 2007-07-03 |
| US20060148693A1 (en) | 2006-07-06 |
| EP1638567B1 (de) | 2012-02-29 |
| ES2383206T3 (es) | 2012-06-19 |
| EP1638567A1 (de) | 2006-03-29 |
| JP2006527737A (ja) | 2006-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO2008013I1 (no) | Sitagliptin, eventuelt i form av et farmasoytisk akseptabelt salt, saerling monofosfatet, pluss metformin, eventuelt i form av et farmasoytisk akseptabelt salt, saerling hydrokloridet | |
| NO20055941L (no) | Anvendelse av en sammensetning omfattende en PDE4-inhibitor og en PDE5-inhibitor | |
| CY1108146T1 (el) | ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ β-ΑΜΙΝΟ-ΕΤΕΡΟΚΥΚΛΙΚΗΣ-ΔΙΠΕΠΤΙΔΥΛΙΚΗΣ ΠΕΠΤΙΔΑΣΗΣ ΓΙΑ ΤΗΝ ΑΓΩΓΗ Ή ΠΡΟΛΗΨΗ ΤΟΥ ΔΙΑΒΗΤΗ | |
| DE60330485D1 (de) | Zur behandlung von diabetes | |
| WO2005032471A3 (en) | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease | |
| TW200728305A (en) | Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease | |
| IS7817A (is) | Fenýlalanín afleiður sem dípeptidýl peptíðasa hindrar til að meðhöndla eða fyrirbyggja sykursýki. | |
| ATE417832T1 (de) | Hexahydrodiazepinone als inhibitoren des dipeptidylpeptidase-iv zur behandlung bzw. prävention von diabetes | |
| TNSN04165A1 (en) | Substituted hydroxyethylamines | |
| ATE540948T1 (de) | Pyrrolopyridine als proteinkinasehemmer | |
| UY28958A1 (es) | Nuevos derivados de piridazin-3(2h)-ona | |
| NO20050851L (no) | Kaspase-inhibitorer og anvendelser derav | |
| WO2004062625A3 (en) | Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease | |
| ATE447574T1 (de) | 3-amino-4-phenylbutansäurederivate als dipeptidylpeptidase-hemmer zur behandlung oder vorbeugung von diabetes | |
| DE60327999D1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
| EA200601212A1 (ru) | Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение | |
| ATE517861T1 (de) | Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| PL1789398T3 (pl) | Pochodne 2-amino-chinazoliny użyteczne jako inhibitory ß-sekretazy (BACE) | |
| EA200601837A1 (ru) | Бензоксазины для лечения заболеваний дыхательных путей | |
| NO20076405L (no) | Anvendelse av 24-nor-UDCA | |
| ATE456955T1 (de) | Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen | |
| ATE457736T1 (de) | Zusammensetzung aus einem pulmonalen surfactant und einem von tnf stammenden peptid | |
| ZA200701850B (en) | Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors | |
| ATE512147T1 (de) | Makrozyklische aminiopyridyl-beta-sekretase- hemmer zur behandlung von morbus alzheimer | |
| ATE349210T1 (de) | Pharazeutische zusammensetzungen aus anticholinergica und p38 kinase hemmern zur behandlung von erkrankungen der atemwege |